Acute Agitation in Emergency Psychiatry

Last updated: December 30, 2024
Sponsor: Lone Baandrup
Overall Status: Active - Recruiting

Phase

2/3

Condition

Manic Disorders

Williams Syndrome

Treatment

Buccal midazolam

Sublingual Dexmedetomidine

Oral lorazepam

Clinical Study ID

NCT06752616
2023-510201-18-00
  • Ages 18-64
  • All Genders

Study Summary

The purpose of the study is to improve the pharmacological treatment of psychiatric patients with acute agitation.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • 18-64 years

  • Agitation with the need for tranquillization in inpatient psychiatric settingsincluding psychiatric emergency rooms

  • Total score of ≥14 on the PANSS Excited Component (PEC)

  • A score ≥4 on at least 1 of the 5 items of the PEC

  • Informed consent obtained prior to the occurrence of the emergency

Exclusion

Exclusion Criteria:

  • Involuntary psychiatric admission according to the Danish Mental Health Act

  • Female patients who are breastfeeding

  • Female patients aged <50 years and unable to perform a negative urine screen forpregnancy and not using safe contraceptives

  • Body weight <50 kg

  • Extreme obesity defined as estimated BMI≥ 40 kg/m2

  • Clinical situations where acute administration of an antipsychotic is preferred totreat acute agitation (in the opinion of the investigator)

  • The patient deemed unwilling or unable to cooperate with study procedures (in theopinion of the investigator)

  • Insufficient language skills that interfere with reading, writing, and providingwritten informed consent in Danish or other available languages (in the opinion ofthe investigator)

  • Clinical suspicion of contraindications for one of the treatment arms

  • Use of benzodiazepines, other sedatives, or antipsychotic drugs in addition to usualtreatment (i.e., additional PN sedative prescriptions) in the 4 hours before studytreatment

  • Known allergy to any of the study medications

Study Design

Total Participants: 132
Treatment Group(s): 3
Primary Treatment: Buccal midazolam
Phase: 2/3
Study Start date:
December 30, 2024
Estimated Completion Date:
December 31, 2027

Study Description

The initial treatment of acute agitation aims to reduce suffering, abort the immediate risk of harm to self or others, and prevent the use of coercive measures such a physical and mechanical restraint. With this research project, we aim to build the initial structure of a visionary platform design and to examine the efficacy, tolerability, and safety of two hitherto under-investigated compounds versus the current standard of care for acutely agitated patients when de-escalation techniques have failed. After obtaining the results of the initial phase, we plan to apply for future funding to maintain and expand the platform design with the addition of relevant experimental arms. The proposed platform design aims to anwer the question What is the best treatment for acutely agitated patients in inpatient psychiatric settings?

Connect with a study center

  • Mental Health Center Copenhagen, Bispebjerg

    Copenhagen N, 2400
    Denmark

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.